Biotech Firm Tiziana Life Sciences to Showcase Drug Candidate at Saudi Innovation Forum
ByAinvest
Tuesday, Sep 30, 2025 9:46 pm ET1min read
TLSA--
Tiziana Life Sciences will showcase its lead drug candidate, foralumab, a fully human anti-CD3 monoclonal antibody. Foralumab is being developed as a nasal spray for neuroinflammation conditions, specifically Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS). The drug has shown promising results in clinical trials, with 14 patients in an open-label Expanded Access Program (EA) Program (NCT06802328) experiencing either an improvement or stability of disease within 6 months [2].
The LSIF 2025 will feature presentations from leading biotech companies, panel discussions, and networking sessions, facilitating investment, collaboration, and strategic partnerships. Tiziana Life Sciences' participation represents an opportunity to engage with global investors and explore potential collaborations to advance its mission of delivering next-generation immunotherapy solutions [1].
Tiziana Life Sciences has been invited to present at the Life Science Innovation Forum in Riyadh, Saudi Arabia. The conference aims to connect drug developers and research groups with investors and policymakers, supporting the country's National Biotechnology Strategy. The company will showcase its lead drug candidate, foralumab, a fully human anti-CD3 monoclonal antibody being developed as a nasal spray for neuroinflammation conditions.
Tiziana Life Sciences, Ltd. (Nasdaq: TLSA), a clinical-stage biopharmaceutical company, has been invited to present at the 2025 Life Science Innovation Forum (LSIF) in Riyadh, Saudi Arabia. The event, scheduled for October 1-2, aims to connect drug developers and research groups with investors and policymakers, aligning with Saudi Arabia's National Biotechnology Strategy [1].Tiziana Life Sciences will showcase its lead drug candidate, foralumab, a fully human anti-CD3 monoclonal antibody. Foralumab is being developed as a nasal spray for neuroinflammation conditions, specifically Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS). The drug has shown promising results in clinical trials, with 14 patients in an open-label Expanded Access Program (EA) Program (NCT06802328) experiencing either an improvement or stability of disease within 6 months [2].
The LSIF 2025 will feature presentations from leading biotech companies, panel discussions, and networking sessions, facilitating investment, collaboration, and strategic partnerships. Tiziana Life Sciences' participation represents an opportunity to engage with global investors and explore potential collaborations to advance its mission of delivering next-generation immunotherapy solutions [1].
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
Comments
No comments yet